Navigation Links
Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
Date:12/14/2010

PARSIPPANY, N.J., Dec. 14, 2010 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, announced today that the New Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for postsurgical pain management, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Pacira submitted the EXPAREL NDA in September 2010 for the initial indication of postsurgical analgesia by local administration. The FDA also notified Pacira that its Prescription Drug User Fee Act (PDUFA) target date (the date the FDA expects to complete its review of the EXPAREL NDA) is July 28, 2011.  

About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. The company's most advanced product candidate, EXPAREL, a bupivacaine-based product, has completed Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.ContactJames S. Scibetta, CFO, Pacira Pharmaceuticals, Inc.973-254-3560
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
4. ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
5. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
6. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
7. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
8. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
10. Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
11. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Oct. 18, 2011 Phreesia, the patient check-in ... of electronic health records (EHR) software and solutions, ... Through this partnership, medical practices nationwide that use ... achieve a seamless patient check-in experience. The automated ...
... Melnik, President & CEO of PediaVisionJeff Mortensen, Vice President ... a revolutionary new vision screening device, which identifies vision ... October 20, Friday October 21 WHY: Spot is ... children across America.   Spot has an incredibly ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3
(Date:7/10/2014)... known as the "Mississippi baby" an infant seemingly cured ... a prolonged remission of HIV infection in The New ... of HIV after more than two years of not taking ... HIV specialist and researchers involved in the case. ... this young child, the medical staff involved in the child,s ...
(Date:7/10/2014)... those students looking to bump up their grade point ... more time in a library or study hall, but ... shows that students who were members of the recreational ... freshman and sophomore years had higher GPAs than those ... students with memberships stayed in school longer. An increase ...
(Date:7/10/2014)... ROCHESTER, Minn. The benefits of medical imaging far ... ordered The Right Way, with The Right Radiation Dose. ... ratio and Mayo Clinic is leading a collaborative effort ... The commentary, published online in the Journal of ... Radiology, the Joint Commission, the Intersociety Accreditation Commission, and ...
(Date:7/10/2014)... illness and even death are likely to result if ... Now, however, a team of researchers based at The ... order of infection, the bacteria Streptococcus pneumoniae ... case of the flu. , The researchers discovered ... a bacterial virulence factor, might protect macrophagesa type of ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
Breaking Medicine News(10 mins):Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:Want a higher GPA in college? Join a gym 2Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Working to loosen the grip of severe mental illness 2
... Authentidate Holding Corp. (Nasdaq: ADAT ), ... workflow management services, today announced financial results for the ... Benjamin, President of Authentidate, stated, "Revenue growth slowed during ... conditions impacted our results. Although total revenues were ...
... of the most harmful forms of teen drug abuse with a hard-hitting ... ... Los Angeles, CA (PRWEB) February 12, 2009 -- Statistics show a dangerous ... office of the DEA announced this week that Phoenix high school students ...
... An investor group in Trinity,Biotech plc (Nasdaq: ... of,diagnostic products, is delighted that Jim Merselis has joined ... support for Mr. Merselis, the,group has scheduled a conference ... am PT) on Tuesday, February 17, 2009. , ...
... advancing the lives,of children and adults experiencing barriers to ... hit the slopes last weekend. Nearly,200 community members, volunteers ... a day of fun, competition and meeting new friends ... The event, at Trollhaugen in Dresser, ...
... SCAN Long Term Care and SCAN Health Plan Arizona, ... of Health Plans. "The new association intends to be ... here in Arizona," said Lescault. "As president I look ... the governor,s office in adjusting the state health budget ...
... CRANBURY, N.J., Feb. 12 Innophos Holdings, Inc. (Nasdaq: ... in North America, today announced the election of John ... is Executive Vice President and Chief Operating Officer of ... of highly engineered specialty chemicals, including polymer additives, catalysts ...
Cached Medicine News:Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 2Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 3Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 4Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 5Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 6Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 7Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 8Health News:Church of Scientology Fighting Teen Drug Abuse 2Health News:Second Annual Courage Cup Race Raises More Than $5,000 for Courage Center's Ski and Snowboard Program 2Health News:SCAN's Thomas Lescault Elected President of New Arizona Association of Health Plans 2Health News:Innophos Holdings, Inc. Elects John M. Steitz as New Independent Director 2
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: